Technology
Pipelines
Research Centers
Reseach Alliance
Business Development
Hanmi's Global Presence
Manufacturing Facilities
Products
Contact us
CEO's message
Stock Information
Financial Reports
Presentations
IR Contact
Latest News
News Archives
Company Profile
Leadership&Management
History
Affiliates
Career Opportunities
Select Category
All Category
Prescription drugs
APIs
OTC drugs
Select Therapeutic
Cardiovascular
CNS
Dermatology
Gastrointestinal
Infection
Metabolism
MuscuLo-skeletal
Oncology
Ophthalmic
Pain/Inflammation
Respiratory
Urology/Gynecology
Others
Research Center
Latest News
Company Profile
Stock information
Business Relationship
Financial Results
Home
> Investors >
Disclosure
47
Annual cash dividend
17, Feb. 2010
46
Interim report of business performance in 2009
02, Feb. 2010
45
Bonus share is issued
23, Dec. 2009
44
Interim report on business performance in 3Q, 2009
28, Oct. 2009
43
Hanmi participated in NDR in EU and USA
13, Oct. 2009
42
Hanmi participated in Merril lynch-BoA conference
13, Oct. 2009
41
Big shareholder's status (Skagen As)
13, Oct. 2009
40
Big shareholder's status (Mirae Asset)
10, Aug. 2009
39
Big shareholder's status (Norges Bank)
07, Aug. 2009
38
Big share holder's status (Mirae Asset)
06, Aug. 2009
37
Biggest shareholder's status (CEO & related parties)
06, Aug. 2009
36
Big share holder's status (Mirae Asset)
31, Jul. 2009
35
Interim Report on Business Performace in 2Q, 2009
31, Jul. 2009
34
Big shareholder's status (NPS)
30, Jul. 2009
33
Biggest shareholder's status (CEO & related parties)
30, Jul. 2009
1
2
3
4
+++Family Site+++
Hanmi Fine Chemical Co., Ltd
Beijing Hanmi Pharmaceutical Co., Ltd
Hanmi FT Co., Ltd
Hanmi IT Co., Ltd
Hanmi Medicare Co., Ltd